bioAffinity Technologies, Inc. (BIAF)
Largest Insider Buys in Sector
BIAF Stock Price History Chart
BIAF Stock Performance
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Insider Activity of bioAffinity Technologies, Inc.
Over the last 12 months, insiders at bioAffinity Technologies, Inc. have bought $0 and sold $0 worth of bioAffinity Technologies, Inc. stock.
On average, over the past 5 years, insiders at bioAffinity Technologies, Inc. have bought $99,997 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,448 shares for transaction amount of $0 was made by Edwards James Michael (Chief Financial Officer) on 2022‑09‑01.
List of Insider Buy and Sell Transactions, bioAffinity Technologies, Inc.
| 2022-09-01 | Chief Financial Officer | 2,448 – | $0 | $0 | -77.35% | |||
| 2022-08-31 | director | 32,652 0.5281% | $3.06 | $99,997 | -77.35% | |||
| 2022-08-31 | Executive Chairman | 40,916 – | $0 | $0 | -77.35% | |||
| 2022-08-31 | director | 8,163 – | $0 | $0 | -77.35% | |||
| 2022-08-31 | President, CEO | 16,326 – | $0 | $0 | -77.35% |
Insider Historical Profitability
| Rubin Gary D | director | 1584144 10.1648% | $0.95 | 1 | 0 | <0.0001% |
| GIRGENTI STEVEN | Executive Chairman | 861099 5.5253% | $0.95 | 1 | 0 | |
| Edwards James Michael | Chief Financial Officer | 30323 0.1946% | $0.95 | 1 | 0 | |
| KNIGHT PETER S | director | 22448 0.144% | $0.95 | 1 | 0 | |
| Zannes Maria | President, CEO | 19897 0.1277% | $0.95 | 1 | 0 |